RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Applied Therapeutics (NASDAQ:APLT) and maintained a $12 price target.
July 17, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Applied Therapeutics (NASDAQ:APLT) and maintained a $12 price target.
The reiteration of an Outperform rating and the maintenance of a $12 price target by RBC Capital is a positive signal for investors. It suggests confidence in the company's future performance, which is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100